Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00364286 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. 5 versions Re-verified since Apr 24, 2018, no change to tracked fieldsv18-v22
  2. Results first posted: Aug 21, 2013 Primary endpoint revisedv17 Show 1 more changeShow less
    • Primary endpoint revised

    See this version in full on ClinicalTrials.gov ↗

  3. Eligibility criteria expanded, about 15 words Study description shortened, about 99 wordsv16 Show 1 more changeShow less
    • Study description shortened, about 99 words

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Active, Not Recruiting to Completed Enrollment target: estimated 25 to confirmed 17 · Primary and study completion dates changed from estimate of Aug 2013 to Nov 2012v15 Show 2 more changesShow less
    • Enrollment target: estimated 25 to confirmed 17
    • Primary and study completion dates changed from estimate of Aug 2013 to Nov 2012
  5. Re-verified, no change to tracked fieldsv14
Show 12 earlier versionsHide 12 earlier versions
  1. Primary and study completion dates: Aug 2012 to Aug 2013v13
  2. Re-verified, no change to tracked fieldsv12
  3. Primary and study completion dates: Aug 2011 to Aug 2012v11
  4. Re-verified, no change to tracked fieldsv10
  5. Primary and study completion dates: Aug 2010 to Aug 2011 Study site revisedv9 Show 1 more changeShow less
    • Study site revised

    See this version in full on ClinicalTrials.gov ↗

  6. Re-verified, no change to tracked fieldsv8
  7. Trial status: Recruiting to Active, Not Recruiting Site details revisedv7 Show 1 more changeShow less
    • Site details revised
  8. Primary completion date: Aug 2008 to Aug 2010 Primary endpoint revised · Completion date: Jul 2009 to Aug 2010 · Secondary endpoints shortened, about 7 wordsv6 Show 3 more changesShow less
    • Primary endpoint revised
    • Completion date: Jul 2009 to Aug 2010
    • Secondary endpoints shortened, about 7 words

    See this version in full on ClinicalTrials.gov ↗

  9. Study description shortened, about 43 wordsv5 See this version in full on ClinicalTrials.gov ↗
  10. Primary endpoints: 7 to 1 Primary completion date: Aug 2008 · Completion date: Jul 2009 · Secondary endpoints expanded, about 7 words · 2 morev4 Show 5 more changesShow less
    • Primary completion date: Aug 2008
    • Completion date: Jul 2009
    • Secondary endpoints expanded, about 7 words
    • Study description expanded, about 86 words
    • Study arms: 0 to 1

    See this version in full on ClinicalTrials.gov ↗

  11. Study Status, Oversight, Study Description, Conditions, Study Design, Eligibility, Contacts/Locationsv3
  12. Eligibility criteria expanded, about 64 words Study description shortened, about 83 wordsv2 Show 1 more changeShow less
    • Study description shortened, about 83 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical research study is to learn if dasatinib can help to control Chronic Lymphocytic Leukemia (CLL). The safety of the drug will also be studied. Optional Procedures: You will be asked to have additional blood samples drawn. These samples will be used to see how the disease is responding to the drug.
Trial Details
NCT Number NCT00364286
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Bristol-Myers Squibb
Conditions Leukemia, Lymphoma
Enrollment 17 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov